[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642561":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":18,"responsibleParty":68,"collaborators":7,"id":70,"slug":7,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":7,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":7,"enrollmentInfo":78,"targetDuration":7,"studyType":81,"phases":7,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Camurus AB","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Octreotide subcutaneous depot","Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study",[14],{"name":5,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+46 46 286 57 30","medicalinfo@camurus.com",[19,31,41,50,59],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Universitaetsklinikum Aachen","NOT_YET_RECRUITING","Aachen","52074","Germany",{"type":26,"coordinates":27},"Point",[28,29],6.08342,50.77664,{"lat":29,"lon":28},{"facility":32,"status":33,"city":34,"state":7,"zip":35,"country":24,"cosmosGeoPoint":36,"geoPoint":40,"contacts":7},"Universitaetsklinikum Leipzig","RECRUITING","Leipzig","04103",{"type":26,"coordinates":37},[38,39],12.37129,51.33962,{"lat":39,"lon":38},{"facility":42,"status":21,"city":43,"state":7,"zip":44,"country":24,"cosmosGeoPoint":45,"geoPoint":49,"contacts":7},"Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie","Magdeburg","39110",{"type":26,"coordinates":46},[47,48],11.63189,52.13129,{"lat":48,"lon":47},{"facility":51,"status":21,"city":52,"state":7,"zip":53,"country":24,"cosmosGeoPoint":54,"geoPoint":58,"contacts":7},"Medicover Neuroendokrinologie MVZ","München","81667",{"type":26,"coordinates":55},[56,57],13.31243,51.60698,{"lat":57,"lon":56},{"facility":60,"status":21,"city":61,"state":7,"zip":62,"country":24,"cosmosGeoPoint":63,"geoPoint":67,"contacts":7},"Universitätsklinikum Würzburg","Würzburg","97080",{"type":26,"coordinates":64},[65,66],9.95121,49.79391,{"lat":66,"lon":65},{"type":69,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100642561",false,"NCT07583563","An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly","A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly","Inclusion Criteria:\n\n* Have started or will be starting treatment with octreotide SC depot for acromegaly\n\nExclusion Criteria:\n\n* Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly\n* Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.","ALL","18 Years",{"count":79,"type":80},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.",[84],"Acromegaly",[11,84,86,87,88,89],"Observational","Real-world","Safety","Tolerability","2026-06-26",{"date":92,"type":93},"2026-06-30","ACTUAL",{"date":95,"type":93},"2026-06-05",{"date":97,"type":80},"2029-06",{"name":5,"class":6},5]